๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› France
Clinical trial register · European Union · CTIS

Clinical Trials in France, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show โ€” this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12479 total CTIS records โ€” a stated recency window, not the full historical archive. Synced 24 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,479
Total on CTIS
full historical archive
743
Phase III
within the shown window
Top member states
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531
Narrow the registerReset
Phase
Phase I 555 Phase I/II 212 Phase II 730 Phase III 743 Phase IV 260
Lead sponsor
AstraZeneca AB 63 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531 Belgium 431 Czechia 331
All 28 states

Trials with a site in France

884 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
2025-522204-24-00Neoplasms, Vomiting, Drug-Related Side Effects and Adverse โ€ฆ
Eli Lilly & Co.
Neoplasms
Romania, Spain, France, Italy
23/02/2026
Phase III
INCA000585-201 - A PHASE 2A, OPEN-LABEL, MULTI-CENTER STUDY OF TAFASITAMAB IN ADULT PARTICIPANTS WITH AUTOIMMUNE BLOOD CELL DISORDERS
2025-521286-27-00Immune-mediated thrombocytopenia, Autoimmune thrombocytopenโ€ฆ
Incyte Corp.
Hemic and Lymphatic Diseases
Netherlands, Italy, Spain, France
23/02/2026
Phase I/II
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
2022-502911-12-00Propionic Acidemia
Moderna Inc.
Nutritional and Metabolic Diseases
Spain, Netherlands, France
23/02/2026
Phase III
A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients
2025-521521-33-00Kidney transplant rejection
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase II
PRODIGE 113 (FFCD 2314) โ€“ REWENEC โ€“ 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic control arm in second line treatment of metastatic neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin. Phase II comparative randomized study โ€“ multicentric
2024-519922-19-00Neuroendocrine carcinoma of gastro-enteropancreatic or unknโ€ฆ
Hospices Civils De Lyon
Neoplasms
France
22/02/2026
Phase III
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
2025-521314-25-00NPM1-m and KMT2A-r Acute Myeloid Leukemia
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase III
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)
2025-522544-40-00Hereditary transthyretin-mediated amyloidosis with polyneurโ€ฆ
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
France, Italy, Greece, Spain, Sweden, Ireland, Cyprus, Portugal, Germany
20/02/2026
Phase I/II
A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults with Chronic Hepatitis B
2025-523619-12-00Chronic Hepatitis B
Nchroma Bio Inc.
Virus Diseases
France
20/02/2026
Phase I
A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)
2025-521438-27-00advanced, unresectable and/or metastatic solid tumors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Sweden, France, Spain, Germany
19/02/2026
Phase I/II
A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours
2025-521164-36-00Patients with relapsed/refractory advanced/metastatic ovariโ€ฆ
Apmonia Therapeutics
Neoplasms
Belgium, France
19/02/2026
Phase I/II
Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease
2024-519412-13-00Canavan Disease, Canavan disease
Myrtelle Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
18/02/2026
Phase III
A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Naรฏve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)
2025-523820-26-00Growth Hormone Deficiency (GHD)
Lumos Pharma LLC
Hormonal diseases
Romania, France, Italy, Poland, Spain
18/02/2026
Phase III
Double blind, multicenter, randomized, controlled trial of dexmedetomidine vs placebo in premature neonates receiving invasive ventilation
2023-509247-27-00Neonatal respiratory distress. Pain and discomfort
Centre Hospitalier Intercommunal Creteil
Anesthesia and Analgesia
France
18/02/2026
Phase III
A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
2025-520897-21-00Multiple Myeloma
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Norway, France, Spain
18/02/2026
Phase III
J2A-MC-GZPR: A Study to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants with Peripheral Artery Disease: A Randomized, Double-Blind, Placebo Controlled Trial
2025-523283-21-00Peripheral Arterial Disease
Eli Lilly & Co.
Cardiovascular Diseases
Slovakia, Poland, France, Netherlands
17/02/2026
Phase III
A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02)
2025-522873-12-00ER+, HER2- Advanced Breast Cancer
Olema Pharmaceuticals Inc.
Neoplasms
Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands
17/02/2026
Phase I/II
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.
2025-522595-87-00Hematological Malignancies
Daiichi Sankyo Inc.
Neoplasms
France, Italy
16/02/2026
Phase II
A phase 2a exploratory study of TAR-0520 gel in prevention of Hand and Foot Syndrome
2025-524008-32-00Capecitabine-induced hand and foot syndrome
Tarian Pharma
Skin and Connective Tissue Diseases
France
16/02/2026
Phase III
A randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes: Victorion โ€“ RIDES
2025-521670-34-00Acute coronary syndrome (ST-elevation myocardial infarctionโ€ฆ
Novartis Pharma AG
Cardiovascular Diseases
Germany, Hungary, Poland, France, Spain
16/02/2026
Phase III
A Phase 2/3, Randomized, Active-Controlled, Open-Label (Phase 2) and Double-Blind (Phase 3) Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily in Treatment-Naรฏve Adult Participants Living With HIV 1
2025-522519-40-00HIV
Merck Sharp & Dohme LLC
Virus Diseases
France, Spain
16/02/2026
Phase I
A Phase 1 Study of IM-1021 in Participants with Advanced Cancer
2025-523160-20-00Advanced B-cell lymphomas, Advanced solid tumors
Immunome Inc.
Neoplasms
France, Spain, Denmark, Italy
16/02/2026
Phase I
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00Locally advanced unresectable or metastatic soft tissue sarโ€ฆ
Novartis Pharma AG
Neoplasms
Germany, Portugal, France, Spain, Denmark
16/02/2026
Phase I
A Phase 1 first-in-human study to evaluate SAR447754 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.
2025-523826-41-00Dermatitis atopic
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, France, Hungary, Poland, Spain, Bulgaria
16/02/2026
Phase II
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above
2025-521416-19-00Recurrence of Clostridioides difficile Infection
AstraZeneca AB
Bacterial Infections and Mycoses
Greece, Spain, France, Germany, Italy, Hungary, Denmark, Sweden
16/02/2026
Phase III
Sustained-release oral morphine to alleviate persistent dyspnea in patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis outside the administration of ventilatory assistance: prospective multicenter randomized, placebo-controlled study, parallel arms. (OPIDYS-ALS).
2025-522546-52-00patients with chronic respiratory insufficiency due to amyoโ€ฆ
Assistance Publique Hopitaux De Paris
Respiratory Tract Diseases
France
13/02/2026
Phase III
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
2025-523533-25-00Cancer-associated Cachexia
CatalYm GmbH
Nutritional and Metabolic Diseases
France, Czechia, Romania, Italy, Germany, Poland, Spain, Bulgaria, Norway, Ireland, Netherlands
13/02/2026
Phase I/II
A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
2025-521671-31-00Relapsed/Refractory (R/R) and Minimal Residual Disease Posiโ€ฆ
Amgen Inc.
Neoplasms
France, Netherlands, Italy
13/02/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)
2025-522279-27-00Newly Diagnosed AML with an NPM1 mutation
Syndax Pharmaceuticals Inc.
Neoplasms
Greece, Poland, Spain, Austria, Italy, Romania, Belgium, France, Lithuania, Germany, Hungary, Czechia, Portugal
13/02/2026
Phase III
HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).
2025-523275-27-00Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyriโ€ฆ
Disc Medicine Inc.
Nutritional and Metabolic Diseases
Italy, France, Ireland, Belgium, Sweden, Germany, Netherlands, Norway, Spain
12/02/2026
Phase III
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00Metastatic colorectal cancer
Summit Therapeutics Inc.
Neoplasms
Belgium, Italy, Spain, Germany, France, Poland, Czechia, Hungary
12/02/2026
Phase III
A Long-term Extension Study of the Safety and Efficacy of Cleminorexton in Participants with Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored Cleminorexton Clinical Trial
2025-522987-34-00Narcolepsy and Idiopathic Hypersomnia
Centessa Pharmaceuticals UK Limited
Nervous System Diseases
France, Spain, Italy
12/02/2026
Phase III
A Randomized, Open-labelled, Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naรฏve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction (SEVENAZA)
2025-521634-29-00ONCOLOGY, Acute Myeloid Leukemia
Institut Gustave Roussy
Immune System Diseases
France, Spain
11/02/2026
Phase III
Evaluation of the efficacy of corticosteroids in septic arthritis in adults: Randomized double-blind controlled trial [CORSAR]
2025-522193-37-00Septic arthritis
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
10/02/2026
Phase I
A phase 1, open-label, dose-escalation and dose-expansion study evaluating the safety, feasability and efficacy of ODI-2001 vaccine, a personalized immunotherapy, in patients with metastatic or locally advanced colon cancer of pancreatic cancer
2025-523172-23-00Metastatic or locally advanced pancreatic cancer, Metastatiโ€ฆ
Centr Georges Francois Leclerc
Digestive System Diseases
France
10/02/2026
Phase II
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment.
2025-523231-19-00Cutaneous Squamous Cell Carcinoma
Philogen S.p.A.
Neoplasms
Italy, Germany, Greece, Spain, Austria, France, Netherlands
10/02/2026
Phase III
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
2024-519504-27-00Relapsed Refractory Multiple Myeloma
Regeneron Pharmaceuticals Inc.
Neoplasms
Greece, Spain, Poland, Italy, Austria, Czechia, Belgium, Germany, Netherlands, France
10/02/2026
Phase III
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-1)
2025-522703-14-00"Moderate to severe obstructive sleep apnea (OSA) in adultsโ€ฆ
Amgen Inc.
Respiratory Tract Diseases
Poland, Germany, Czechia, Hungary, Spain, France
10/02/2026
Phase III
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy andโ€ฏSafety ofโ€ฏEmpasiprubartโ€ฏIV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
2025-520805-10-00Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
Nervous System Diseases
Czechia, Denmark, Poland, Slovenia, Netherlands, Austria, Estonia, Slovakia, Hungary, Finland, Bulgaria, France, Italy, Greece, Romania
10/02/2026
Phase II
A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to less than 18 Years of age With Generalized Myasthenia Gravis (gMG)
2025-520993-20-00Generalized Myasthenia Gravis
Amgen Inc.
Nervous System Diseases
Spain, Italy, Poland, France
09/02/2026
Phase I/II
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants with Invasive Ventilator-dependent X-linked Myotubular Myopathy
2025-523213-29-00X-linked myotubular myopathy
Astellas Gene Therapies Inc.
Musculoskeletal Diseases
France
09/02/2026
Phase I
A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor
2025-522033-64-00Myelofibrosis
Ajax Therapeutics Inc.
Neoplasms
Italy, France, Spain
09/02/2026
Phase I
A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC
2025-522543-18-00Advanced Clear Cell Renal Cell Carcinoma
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Spain, France
09/02/2026
Phase I
A trial to test the safety and tolerability of Lu AH70212 and Lu AH69593 in healthy adults.
2025-522652-58-01Narcolepsy
H. Lundbeck A/S
Nervous System Diseases
France
09/02/2026
Phase IV
Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
2025-521621-33-00Hepatocellular Carcinoma, Melanoma, Metastatic Melanoma, Adโ€ฆ
Replimune Group Inc.
Neoplasms
Germany, Greece, France, Poland, Spain
09/02/2026
Phase III
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination with Osimertinib, Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713
2025-521124-29-00Non-Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Portugal, Italy, Spain, Poland, Netherlands, Germany, Belgium, Austria, France
09/02/2026
Phase III
A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema โ€“ ORBIT-EXPANSE
2025-521142-22-00Hereditary Angioedema
Astria Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Netherlands, Spain, Poland, Germany, Czechia, Austria, Portugal, Hungary, France, Italy, Bulgaria
09/02/2026
Phase III
A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis
2025-521038-27-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Germany, Austria, Italy, Czechia, Netherlands, Poland, Belgium, Hungary, Lithuania, Greece, France, Bulgaria, Spain, Norway
09/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis.
2025-521035-37-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Austria, France, Norway, Hungary, Bulgaria, Netherlands, Czechia, Slovakia, Germany, Lithuania, Greece, Belgium, Italy, Spain, Poland
09/02/2026
Phase II
A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI)- (299AR201-TRANSPIRE)
2025-521742-15-00Treatment of Late Isolated Microvascular Inflammation in Reโ€ฆ
Biogen Idec Research Limited
Immune System Diseases
Germany, Austria, Spain, Czechia, France
09/02/2026
Phase II
A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis
2025-522892-27-00Bronchiectasis
GSK PLC
Respiratory Tract Diseases
Denmark, France, Spain, Italy, Germany, Poland
09/02/2026
Phase I/II
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
2024-519881-32-00Sickle Cell Disease
Novo Nordisk A/S
Hemic and Lymphatic Diseases
France
06/02/2026
Phase II
A PET-MRI study of serotoninergic brainstem pathway in patients with Dravet Syndrome - DRAPETONINE
2025-524199-40-00neurology
Hospices Civils De Lyon
Nervous System Diseases
France
06/02/2026
Phase III
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
2025-522229-37-00Gastrointestinal Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
France, Romania, Spain, Netherlands, Norway, Belgium, Hungary, Italy, Poland, Germany
06/02/2026
Phase IV
Efficacy of MIrikizumab to achieve traNsmural healing in patiENTs with Crohnโ€™s Disease : EMINENT CD
2025-521889-95-00Crohn's Disease
Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif
Digestive System Diseases
France
05/02/2026
Phase I
A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor
2025-524385-18-00Non-alcoholic steatohepatitis
Inventiva
Digestive System Diseases
France
04/02/2026
Phase I
A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
2025-521394-13-00Relapsed/refractory Acute Myeloid Leukemia or relapsed/refrโ€ฆ
Auron Therapeutics Inc.
Neoplasms
France
04/02/2026
Phase II
An Open-Label Extension, Multi-centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants with Multiple System Atrophy
2025-521642-14-00Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC
Nervous System Diseases
France, Germany, Italy, Spain
04/02/2026
Phase II
An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer with Liver Dominant Disease
2025-521966-91-00Refractory Metastatic Breast Cancer with Liver Dominant Disโ€ฆ
Delcath Systems Inc.
Neoplasms
Italy, Spain, Sweden, France, Germany
04/02/2026
Phase III
A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
2025-522015-42-00Chronic Hepatitis D Infection
Mirum Pharmaceuticals Inc.
Virus Diseases
Czechia, Austria, Spain, Romania, Germany, Italy, France
03/02/2026
Phase I/II
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04โ€“Substudy 04D
2025-522253-19-00Urothelial carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Netherlands, France, Spain
03/02/2026
Phase III
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
2025-522960-34-00Hypertension, Established cardiovascular disease, High cardโ€ฆ
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase III
MAMI Use of the Methoxyflurane as pain-killer in the prehospital management of Acute Myocardial Infarction
2025-523349-86-00Acute Myocardial Infarction
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
02/02/2026
Phase III
NACRE 2_Randomized phase III study evaluating two treatment strategies for locally advanced rectal cancer in patients โ‰ฅ75 years old
2025-521619-37-00Patients โ‰ฅ75 years old with cT3/T4 rectal adenocarcinoma elโ€ฆ
Unicancer
Neoplasms
France
02/02/2026
Phase I
A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC
2025-522914-22-00Locally Advanced Head and Neck Squamous Cell Carcinoma (LA โ€ฆ
Janssen Cilag International
Neoplasms
France, Spain
02/02/2026
Phase II
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)
2025-521560-36-00Type 1 Diabetes
Sab Biotherapeutics Inc.
Nutritional and Metabolic Diseases
Austria, Germany, Poland, Italy, Denmark, Spain, Belgium, Finland, France, Lithuania, Slovenia
02/02/2026
Phase III
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
2025-522553-19-00Symptomatic genetic and familial dilated cardiomyopathy.
Kardigan Inc.
Cardiovascular Diseases
Spain, Denmark, Belgium, Hungary, Italy, Poland, France, Sweden, Netherlands
30/01/2026
Phase III
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)
2025-522387-32-00Uveal Melanoma
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany
29/01/2026
Phase II
Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)
2025-522533-54-00Metastatic Non-small cell lung cancer (NSCLC) and Pancreatiโ€ฆ
Institut Gustave Roussy
Neoplasms
France
28/01/2026
Phase III
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
2024-520140-42-00Patients with primary HPV high-grade squamous intra-epithelโ€ฆ
Institut Gustave Roussy
Neoplasms
France
28/01/2026
Phase II
A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis
2025-521636-10-00Progressive Forms of Multiple Sclerosis (PMS)
F. Hoffmann-La Roche AG
Nervous System Diseases
Germany, Spain, France, Hungary, Italy, Poland, Portugal
28/01/2026
Phase III
An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)
2025-522792-29-00Alpha-1 Antitrypsin Deficiency
Grifols Therapeutics LLC
Respiratory Tract Diseases
Poland, Denmark, Netherlands, Ireland, Sweden, Spain, Portugal, Germany, France
27/01/2026
Phase III
N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
2025-522674-36-00Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Czechia, France, Netherlands, Bulgaria, Norway, Austria, Poland, Spain, Italy, Hungary, Germany, Romania, Sweden, Portugal, Belgium
27/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
2025-521558-40-00Pulmonary Hypertension Associated with Interstitial Lung Diโ€ฆ
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase I/II
Evaluation of a [68Ga] Ga-HER2 single domain antibody PET/CT for predicting pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in HER2-positive early breast cancer
2025-523286-23-00Breast Cancer
Centre Henri Becquerel
Not possible to specify
France
26/01/2026
Phase III
Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-POsitive Metastatic Breast Cancer with Proactive Toxicity ManagementReflecting Real-World Clinical Practice / TOP-REAL Trial
2025-521805-41-00Patients with HER2-positive, locally advanced or metastaticโ€ฆ
Solti Group
Neoplasms
France, Germany, Spain
26/01/2026
Phase III
An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants with Heterozygous Familial Hypercholesterolemia
2024-519068-42-00โ€‹Heterozygous Familial Hypercholesterolemiaโ€‹ in pediatric pโ€ฆ
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland
26/01/2026
Phase II
SARUPANC - A multicentric, single arm, phase II trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
2024-516558-24-00Pancreatic (PAAD)
Centre Leon Berard
Neoplasms
France
23/01/2026
Phase III
CIRAANO: Multimodal exploration (including radiopharmaceuticals Amyvidยฎ and Tauvidยฎ) of theater actors, memory athletes, and patients with various memory pathologies: evaluation of mnesic strategies and their cerebral substrates, and contribution to the treatment of memory pathologies.
2025-523264-21-00Semantic Variant Primary Progressive Aphasia, Alcohol Use Dโ€ฆ
Institut National De La Sante Et De La Recherche Medicale
Mental Disorders
France
23/01/2026
Phase II
Evaluation of Tildrakizumab in the Treatment of Ocular Sequelae in Lyell syndrome
2025-522556-10-01Ocular Sequelae in Lyell syndrome
TOXILYON
Eye Diseases
France
23/01/2026
Phase II
Master Protocol: A Phase 1b / 2, Multicenter, Multi Arm Study of Evorpacept in Combination with Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09) Substudy Protocol: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer (ASPEN-09-03)
2025-522012-16-00Breast Cancer
Alx Oncology Holdings Inc.
Neoplasms
Spain, Italy, France
23/01/2026
Phase III
Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)
2025-521792-31-01Homozygous Familial Hypercholesterolemia (HoFH)
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Greece, France, Belgium, Germany, Netherlands, Austria, Sweden, Spain, Czechia, Italy
23/01/2026
Phase II
A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of oral VH4524184 Coadministered with Emtricitabine and Tenofovir Alafenamide in Treatment Naรฏve Viremic Persons with HIV-1.( INNOVATE Study)
2025-521918-26-00HIV Infections
Viiv Healthcare UK Limited
Virus Diseases
Spain, Belgium, France, Germany, Italy, Portugal, Poland
23/01/2026
Phase I
An Experimental Medicine multicenter Trial to evaluate the safety and immunogenicity of experimental versus authorized SARS-CoV-2 vaccine candidates as a booster dose in healthy participants previously vaccinated with authorized mRNA SARS-CoV-2 vaccines.
2025-520652-28-00healthy participants
ANRS Maladies Infectieuses Emergentes
Pathological Conditions, Signs and Symptoms
France
21/01/2026
Phase II
Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER : a pilot study
2025-522743-18-00Gambling disorder
Centre Hospitalier Universitaire De Nantes
Behavior and Behavior Mechanisms
France
21/01/2026
Phase II
J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma
2025-522640-41-00Asthma
Eli Lilly & Co.
Respiratory Tract Diseases
Germany, Netherlands, France, Poland
21/01/2026
Phase I/II
A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF SINGLE AND MULTIPLE ASCENDING DOSES OF BCX17725 IN HEALTHY PARTICIPANTS AND MULTIPLE DOSES OF BCX17725 IN PARTICIPANTS WITH NETHERTON SYNDROME
2025-521973-16-00Netherton Syndrome
Biocryst Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
France, Netherlands, Germany
20/01/2026
Phase III
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations
2025-521284-12-00Non-small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Austria, Portugal, Netherlands, Greece, Belgium, Spain, Germany, France, Romania, Sweden, Italy, Denmark
19/01/2026
Phase III
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
2025-521908-22-00EGFR-mutated Non-small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Poland, Germany, Italy, Norway, Netherlands, Belgium, Romania, France, Greece, Spain
19/01/2026
Phase II
A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)
2025-521606-18-00Ovarian Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Czechia, France, Belgium, Denmark
19/01/2026
Phase III
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK)
2023-503766-24-00Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Romania, Bulgaria, Germany, Spain, Czechia, France, Hungary, Italy, Sweden, Poland, Denmark, Belgium
19/01/2026
Phase I/II
DREPAMIR - A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ enriched cell fraction that contains autologous CD34+ cells transduced ex vivo by the bifunctional ฮฒAS3m/miR7m lentiviral vector expressing the ฮฒAS3m and a micro-RNA (miRNA) targeting specifically the endogenous ฮฒS-globin mRNA in Patients with Sickle Cell Disease (SCD)
2025-521257-17-00SCD severe patients
Assistance Publique Hopitaux De Paris
Hemic and Lymphatic Diseases
France
16/01/2026
Phase I/II
A Phase 1/2 dose escalation trial with administration schedule exploration evaluating single agent TD001, a PSMA-targeted antibody-drug conjugate, in patients with PSMA-expressing metastatic castration-resistant prostate cancer
2025-523273-41-00Metastatic castration-resistant prostate cancer
T.O.A.D. Oncology S.A.
Neoplasms
Spain, France
16/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
2025-521845-26-00BP-I mania or mania with mixed features
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Romania, Poland, France, Italy, Denmark, Bulgaria
15/01/2026
Phase III
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naรฏve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025-521917-24-00Treatment-Naรฏve Recurrent/Metastatic Head and Neck Squamousโ€ฆ
Janssen Cilag International
Neoplasms
Italy, Portugal, Spain, Romania, Hungary, France, Czechia, Germany, Netherlands, Austria, Poland, Belgium
14/01/2026
Phase II
A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis
2025-521503-43-00Atopic dermatitis
Novartis Pharma AG
Skin and Connective Tissue Diseases
France, Germany, Poland, Czechia, Bulgaria
14/01/2026
Phase I
A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)
2025-522398-12-00Locally advanced or metastatic NSCLC
Astellas Pharma Global Development Inc.
Neoplasms
France, Spain
14/01/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.
2024-520353-21-00Myeloproliferative Neoplasms
Incyte Corp.
Neoplasms
Norway, Germany, France, Italy
14/01/2026
Phase I/II
A Phase 1/2, multicentre, open-label clinical trial of DT-7012 as monotherapy and in combination with an immune checkpoint inhibitor in participants with selected advanced solid tumours
2025-523758-15-00Cancer
Domain Therapeutics Australia Pty Limited
Neoplasms
France
14/01/2026
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
2025-521514-26-00Persistent, Recurrent, or Newly Diagnosed Metastatic Cervicโ€ฆ
Merck Sharp & Dohme LLC
Neoplasms
Greece, Ireland, France, Belgium, Czechia, Hungary, Austria, Spain, Sweden, Germany, Poland, Denmark, Italy
14/01/2026
Phase II
A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA)
2025-522232-13-00Sepsis-associated acute kidney injury (AKI)
AstraZeneca AB
Not possible to specify
Germany, France, Spain, Italy, Belgium, Czechia, Greece, Denmark, Hungary
14/01/2026
Rows per page Showing 501–600 of 884
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-europe/country/france?page=6

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,479 trial records at the last sync on 24 Sep 2026, 03:17 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 884 of those trials with a site in France.

How many recently authorised EU trials have a site in France?

884 of the 2,500 most recently authorised trials in this register list a site in France; 408 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.